GS010: Topline Results at Week 48 of the RESCUE Phase III clinical trial
Replay of the Webcast & Conference call available
Our products and pipeline
Our technologies
News & Media
GenSight Biologics announces publication of positive safety data from Phase I/II trial of GS010 in the JAMA Ophthalmology
GenSight Biologics reports topline results at Week 48 of the RESCUE Phase III clinical trial of GS010 in subjects within six months of visual loss onset due to Leber Hereditary Optic Neuropathy (LHON)
GenSight Biologics Updates its 2019 Financial Calendar
GENSIGHT BIOLOGICS S.A.
74, rue du Faubourg Saint-Antoine
75012 Paris
FRANCE
74, rue du Faubourg Saint-Antoine
75012 Paris
FRANCE
+33 1 76 21 72 20
Contact us